BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...


Embrex, now a part of Zoetis (NYSE: ZTS), a global animal health company, developed and launched the world’s first commercial in ovo vaccination device more than 20 years ago. Its Inovoject® System is considered to be the industry standard for in ovo technology, revolutionized automation in the hatchery. Pfizer’s animal health division acquired Embrex in 2007.
Website